Showing results (2541-2550 of 3,353) with videos related to

Sort By:
Pageof 336
Pharmacoeconomics|February 21, 2018
German Value Set for the EQ-5D-5LKristina Ludwig, J-Matthias Graf von der Schulenburg, Wolfgang Greiner
Pharmacoeconomics|February 16, 2018
Different Methods for Modelling Severe Hypoglycaemic Events: Implications for Effectiveness, Costs and Health UtilitiesEdna Keeney, Dalia Dawoud, Sofia Dias
Pharmacoeconomics|February 15, 2018
Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature ReviewLucia Sara D'Angiolella, Paolo Angelo Cortesi, Alessandra Lafranconi, et al.
Pharmacoeconomics|October 29, 2017
Systematic Review of Validity Assessments of Framingham Risk Score Results in Health Economic Modelling of Lipid-Modifying Therapies in EuropeJonas Hermansson, Thomas Kahan
Pharmacoeconomics|January 6, 2019
Modeling Covariate-Adjusted Survival for Economic Evaluations in OncologyIstvan M Majer, Jean-Gabriel Castaigne, Stephen Palmer, et al.
Pharmacoeconomics|October 28, 2006
Using value of information analysis to prioritise health research: some lessons from recent UK experienceKarl P Claxton, Mark J Sculpher
Pharmacoeconomics|March 6, 2007
Enzyme replacement therapy in orphan and ultra-orphan diseases: the limitations of standard economic metrics as exemplified by Fabry-Anderson diseaseDavid F Moore, Markus Ries, Evelyn L Forget, et al.
Pharmacoeconomics|March 6, 2007
Do drugs reduce utilisation of other healthcare resources?Pierre-Yves Crémieux, Pierre Ouellette, Patrick Petit
Pharmacoeconomics|March 6, 2007
Recombinant erythropoietin for chemotherapy-related anaemia: economic value and health-related quality-of-life assessment using direct utility elicitation and discrete choice experiment methodsDiego F Ossa, Andrew Briggs, Emma McIntosh, et al.
Pharmacoeconomics|December 29, 2006
Rates and probabilities in economic modelling: transformation, translation and appropriate applicationRachael L Fleurence, Christopher S Hollenbeak
Pageof 336